Organotypic DRG-peripheral nerve culture system

Patent metadata

Field	Value
Publication number	US-12326440-B2
Application number	US-202418622012-A
Country	US
Kind code	B2
Filing date	Mar 29, 2024
Priority date	May 28, 2015
Publication date	Jun 10, 2025
Grant date	Jun 10, 2025

Abstract

Techniques and systems are disclosed for a bioassay that is an in vitro mimic of peripheral nerve generation using the sensory neurons that innervate the peripheral nervous system. In some embodiments, the techniques may assist in detecting the bioactivity or potency of nerve grafts (e.g., processed, acellular human allografts) for fostering or supporting peripheral nerve regeneration. In various embodiments, techniques comprise affixing a harvested sensory neuron (e.g., a DRG) to a nerve graft segment to form a test construct; culturing the test construct in a medium; analyzing the test construct to indicate the amount of outgrowing peripheral nerve structure; and determining the potency of the nerve graft from a metric derived from the analysis. In some embodiments, techniques and materials may be used to test the effect of a varied test condition on peripheral nerve growth.

First claim

What is claimed is:

1. A method for testing the effect of a condition on nerve outgrowth, the method comprising:
treating an acellular nerve graft segment of an acellular nerve graft in accordance with a study protocol, wherein the acellular nerve graft comprises an endoneurial tube scaffold, an inner surface of an endoneurial tube in the scaffold comprising laminin;
affixing a neuron or a group of neurons to a first end of the treated acellular nerve graft segment to form a test construct;
culturing the test construct in a medium for a period of time to allow nerve outgrowth from the neuron or the group of neurons into the acellular nerve graft segment;
performing an analysis of the test construct, wherein the analysis indicates an amount of an outgrowing nerve structure, wherein performing the analysis of the test construct includes:
measuring a length from the first end of the acellular nerve graft segment on which the neuron or the group of neurons is affixed to an end of each of at least three longest nerve structures within the acellular nerve graft segment, and
averaging the measured length of the at least three longest nerve structures; and

determining the effect of the study protocol by comparing one or more analysis metrics derived from the analysis to one or more control metrics determined from nerve graft segments not treated with the study protocol.

2. The method of claim 1 , wherein the study protocol comprises one or more of:
submerging the acellular nerve graft segment in solution comprising a test compound;
dosing the acellular nerve graft segment with radiation or heat;
dosing the acellular nerve graft segment with an outgrowth inhibiting agent;
mechanically modifying the microstructure or macrostructure of the acellular nerve graft segment;
dosing the acellular nerve graft segment with an outgrowth promoting agent;
applying an electrical field to the acellular nerve graft segment; and
seeding the acellular nerve graft segment with stem cells or Schwann cells.

3. The method of claim 2 , wherein the study protocol comprises at least the dosing the nerve graft segment with the outgrowth inhibiting agent, and wherein the outgrowth inhibiting agent is selected from the group consisting of:
agents that degrade proteins;
agents that disrupt the microstructure or macrostructure of the acellular nerve graft segment;
materials that modify the chemical structure of the acellular nerve graft segment; and
functional blocking antibodies.

4. The method of claim 1 , wherein performing the analysis of the test construct comprises:
preparing the test construct for sectioning;
sectioning the test construct into a plurality of sections, wherein each of the plurality of sections is removed longitudinally at a predetermined distance from a side of the nerve graft segment perpendicular to the first end; and
staining each section with one or more stains.

5. The method of claim 4 , wherein preparing the test construct for sectioning comprises fixing the test construct and paraffin-embedding the test construct.

6. The method of claim 4 , wherein one of the one or more stains is selected from the group consisting of βIII-Tubulin antibody staining, PGP9.5 antibody staining, and S100 antibody staining.

7. The method of claim 1 , wherein performing the analysis of the test construct comprises:
scanning all or part of the test construct with diffusion tensor imaging and producing a tractography image, wherein the outgrowing nerve structure is identified by the tractography image; and
quantifying the amount of outgrowing nerve structure from the tractography image.

8. The method of claim 1 , further comprising passivating the nerve graft segment prior to affixing the neuron or group of neurons onto the nerve graft segment.

9. The method of claim 1 , wherein the affixing of the neuron or group of neurons onto the treated nerve graft segment comprises securing the neuron or group of neurons to the nerve graft segment with a collagen gel.

10. The method of claim 1 , wherein the period of time for culturing is from about 3 days to about 7 days.

11. The method of claim 1 , wherein the neuron or the group of neurons is a dorsal root ganglia (DRG) explant.

12. The method of claim 1 , wherein the outgrowing nerve structure is a neurite or a Schwann cell.

13. The method of claim 1 , wherein the acellular nerve graft segment is taken from an acellular processed nerve allograft.

14. The method of claim 1 , wherein the nerve graft segment is taken from a human.

15. The method of claim 1 , wherein the nerve graft segment is taken from an animal.

Assignees

• Axogen Corp

Inventors

• Deister Curt

Classifications

• G01N33/56966

  Animal cells · CPC title

• G01N33/5026

  on cell morphology · CPC title

• G01R33/5608

  Data processing and visualization specially adapted for MR, e.g. for feature analysis and pattern recognition on the basis of measured MR data, segmentation of measured MR data, edge contour detection on the basis of measured MR data, for enhancing measured MR data in terms of signal-to-noise ratio by means of noise filtering or apodization, for enhancing measured MR data in terms of resolution by means for deblurring, windowing, zero filling, or generation of gray-scaled images, colour-coded images or images displaying vectors instead of pixels (image data processing or generation, in general G06T) · CPC title

• G01R33/56341

  Diffusion imaging · CPC title

• G01N33/50

  Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing (measuring or testing processes involving enzymes or microorganisms, compositions or test papers therefor; processes for forming such compositions, condition responsive control in microbiological or enzymological processes C12Q) · CPC title